{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:26:53Z","timestamp":1769639213680,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.pathol.2023.12.415","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T05:08:49Z","timestamp":1707973729000},"page":"556-564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The frequency and clinical outcome of mono-hit and multi-hit TP53 aberrations in newly diagnosed multiple myeloma"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2626-4154","authenticated-orcid":false,"given":"Sreejesh","family":"Sreedharanunni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6742-7727","authenticated-orcid":false,"given":"Shelly","family":"Singla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Balakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9089-1721","authenticated-orcid":false,"given":"Archana","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6860-3698","authenticated-orcid":false,"given":"Manu","family":"Jamwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namrata","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8189-8128","authenticated-orcid":false,"given":"Charanpreet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6426-0309","authenticated-orcid":false,"given":"Aditya","family":"Jandial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepesh","family":"Lad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2980-8914","authenticated-orcid":false,"given":"Praveen","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man Updesh Singh","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8938-5423","authenticated-orcid":false,"given":"Reena","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2023.12.415_bib1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2023.12.415_bib2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.415_bib3","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.415_bib4","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pathol.2023.12.415_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A\u00a0high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2023.12.415_bib6","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.3324\/haematol.2017.168872","article-title":"The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma","volume":"102","author":"Thanendrarajan","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2023.12.415_bib7","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.415_bib8","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2023.12.415_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/ijlh.13731","article-title":"The success rate of interphase fluorescence in situ hybridization in plasma cell disorders can be improved using unconventional sources of plasma cells","volume":"44","author":"Panakkal","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.pathol.2023.12.415_bib10","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","article-title":"Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders","volume":"97","author":"Ross","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2023.12.415_bib11","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2023.12.415_bib12","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/leu.2017.179","article-title":"Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients","volume":"32","author":"Shah","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2023.12.415_bib13","first-page":"536","article-title":"Observation on frequency and clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India","volume":"144","author":"Kadam Amare","year":"2016","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.pathol.2023.12.415_bib14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.31557\/APJCP.2019.20.1.235","article-title":"Cytogenetic abnormalities in multiple myeloma patients at a tertiary healthcare center in India","volume":"20","author":"Govindasamy","year":"2019","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.pathol.2023.12.415_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41408-019-0264-y","article-title":"Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma","volume":"9","author":"Yellapantula","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.pathol.2023.12.415_bib16","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1111\/bjh.16547","article-title":"Diagnostic deep-targeted next-generation sequencing assessment of TP53 gene mutations in multiple myeloma from the whole bone marrow","volume":"189","author":"Petrackova","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2023.12.415_bib17","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1182\/bloodadvances.2019001275","article-title":"Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma","volume":"4","author":"Mellors","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2023.12.415_bib18","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1182\/blood-2022-159272","article-title":"TP53 gene deletion or mutation in newly diagnosed multiple myeloma patients by FISH with cytoscan arrays and targeted panel sequencing","volume":"140","author":"You","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.415_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106577","article-title":"The frequency and clinico-hematological characteristics of gain(1q21) positive myeloma in an Indian cohort","volume":"105","author":"Panakkal","year":"2021","journal-title":"Leuk Res"},{"key":"10.1016\/j.pathol.2023.12.415_bib20","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1182\/blood.V128.22.4455.4455","article-title":"Prevalence of TP53 mutations in Del(17p) myeloma: spectrum of mutations and effect on survival","volume":"128","author":"Chin","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.415_bib21","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood.V128.22.3271.3271","article-title":"Multiple myeloma with a deletion of chromosome 17p: TP53 mutations are highly prevalent and negatively affect prognosis","volume":"128","author":"Hofste op Bruinink","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.415_bib22","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3324\/haematol.2010.023697","article-title":"Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma","volume":"95","author":"Lod\u00e9","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2023.12.415_bib23","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/jclinpath-2018-205195","article-title":"Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing","volume":"71","author":"Ryland","year":"2018","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.pathol.2023.12.415_bib24","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.415_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-019-0191-y","article-title":"Natural history of multiple myeloma with de novo del(17p)","volume":"9","author":"Lakshman","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.pathol.2023.12.415_bib26","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1080\/10428194.2021.1948032","article-title":"At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China","volume":"62","author":"Shen","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pathol.2023.12.415_bib27","doi-asserted-by":"crossref","first-page":"e685","DOI":"10.1016\/j.clml.2022.03.005","article-title":"Presentation and impact of double and triple hit cytogenetics in patients with multiple myeloma in the real world","volume":"22","author":"Singh","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.pathol.2023.12.415_bib28","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/hon.3063","article-title":"The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: a next generation sequencing retrospective study","volume":"40","author":"De Luca","year":"2022","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.pathol.2023.12.415_bib29","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood-2004-04-1363","article-title":"p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation","volume":"105","author":"Chang","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.415_bib30","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My\u00e9lome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.12.415_bib31","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-14-2576","article-title":"The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma","volume":"21","author":"An","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2023.12.415_bib32","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/sj.leu.2404524","article-title":"Clinical significance of TP53 mutation in myeloma","volume":"21","author":"Chng","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2023.12.415_bib33","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s00277-018-3316-7","article-title":"Evaluation of revised international staging system (R-ISS) for transplant-eligible multiple myeloma patients","volume":"97","author":"Gonz\u00e1lez-Calle","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.pathol.2023.12.415_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.pathol.2023.12.415_bib35","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European myeloma network (EMN) report within the HARMONY project","volume":"40","author":"D\u2019Agostino","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.12.415_bib36","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/s41375-018-0037-9","article-title":"Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups","volume":"32","author":"Bolli","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2023.12.415_bib37","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1200\/EDBK_159017","article-title":"Next-generation sequencing informing therapeutic decisions and personalized approaches","volume":"35","author":"Szalat","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302524000576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302524000576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T07:12:12Z","timestamp":1715325132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302524000576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0031302524000576"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2023.12.415","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The frequency and clinical outcome of mono-hit and multi-hit TP53 aberrations in newly diagnosed multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2023.12.415","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}